For the first time ever, Medicare has successfully negotiated with pharmaceutical manufacturers to reduce the prices of ten of the most expensive prescription drugs for consumers enrolled in Medicare Part D. These new prices are set to take effect in 2026, offering discounts of nearly 79%.
The list of discounted drugs includes Janssen Biotech's Stelara (JNJ), Janssen Pharmaceutical's Xarelto, Bristol Myers Squibb's Eliquis (BMY), Novartis's Entresto (NVS), Pharmacyclics's Imbruvica (ABBV), Merck's Januvia (MRK), Novo Nordisk's Fiasp (NVO), AstraZeneca's Farxiga (AZN), Immunex's Enbrel (AMGN), and Boehringer Ingelheim's Jardiance.
Yahoo Finance senior health reporter Anjalee Khemlani breaks down the details.
Catch the full interview with Dr. Meena Seshamani, Center for Medicare and Medicaid Services Deputy Administrator and Director of the Center for Medicare, on this topic.
For more expert insight and the latest market action, click here to watch this full episode of Wealth!
This post was written by Angel Smith